Sen. Bill Cassidy plots a path for more commercially viable cell and gene therapies
With the likely approval of a new gene editing therapy coming this week for CRISPR Therapeutics and Vertex, Sen. Bill Cassidy (R-LA) on Tuesday called on insurers to provide a clearer road map on how they plan to cover the expensive but potentially cost-saving therapies.
Cassidy, who forged a subscription-like deal to expand access to new hepatitis C cures in his state, is now debating how best to help the field of cell and gene therapies. His office notes that more than one million patients may receive a gene therapy by the end of 2034, with spending eclipsing $12 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
